세계의 임상시험용 의약품 CDMO 시장

Global Investigational New Drug CDMO Market to Reach US$15.8 Billion by 2030

The global market for Investigational New Drug CDMO estimated at US$11.3 Billion in the year 2024, is expected to reach US$15.8 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Small Molecule, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Large Molecule segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 5.7% CAGR

The Investigational New Drug CDMO market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Investigational New Drug CDMO Market - Key Trends & Growth Drivers Summarized

The Contract Development and Manufacturing Organization (CDMO) market for Investigational New Drugs (INDs) has become a critical component in the pharmaceutical and biotechnology industries. As pharmaceutical companies continue to focus on innovation while outsourcing drug development and manufacturing, CDMOs play a vital role in accelerating the path from preclinical research to clinical trials. IND CDMOs specialize in offering end-to-end solutions, including formulation development, clinical trial material manufacturing, regulatory support, and analytical services, enabling pharmaceutical firms to navigate the complex drug approval process efficiently. Given the increasing complexity of drug molecules, stringent regulatory requirements, and growing demand for specialized expertise, the role of CDMOs in the IND market is expanding rapidly, shaping the future of drug development worldwide.

How Are Technological Advancements Transforming IND CDMO Services?

The IND CDMO market is undergoing a significant transformation driven by technological innovations that enhance efficiency, compliance, and speed in drug development. One of the most important advancements is the integration of continuous manufacturing techniques, which streamline production processes, minimize waste, and improve product consistency. Unlike traditional batch manufacturing, continuous manufacturing allows for real-time quality monitoring, reducing the risk of variability and improving scalability for early-phase drug production.

Another breakthrough in the industry is the use of artificial intelligence (AI) and machine learning (ML) in drug formulation and process optimization. AI-driven predictive modeling helps CDMOs identify the most effective drug formulations, optimize stability conditions, and enhance process efficiencies. Additionally, automation and robotics in laboratory and manufacturing environments have improved precision in compound handling, minimizing human errors and ensuring reproducibility in IND production. The adoption of single-use bioprocessing technologies is another trend gaining momentum, particularly in biologics and cell and gene therapy manufacturing. These disposable systems reduce contamination risks, lower operational costs, and enhance flexibility, making them ideal for early-stage clinical production.

What Market Trends Are Reshaping the IND CDMO Landscape?

The IND CDMO market is witnessing several key trends that are reshaping its growth trajectory. One of the most prominent trends is the increasing demand for specialized CDMO services in biologics and advanced therapies. With the rapid expansion of monoclonal antibodies, cell and gene therapies, and RNA-based drugs, pharmaceutical companies are seeking CDMOs with expertise in handling complex biologic formulations, requiring specialized infrastructure and regulatory knowledge. This shift is prompting many CDMOs to invest heavily in biopharmaceutical production capabilities, including high-containment facilities for viral vector and mRNA-based therapeutics.

Another significant trend is the globalization of IND CDMO services, with companies expanding their operations across North America, Europe, and Asia-Pacific. Emerging markets, particularly in China and India, are witnessing rapid growth in CDMO capabilities due to cost advantages, skilled workforce availability, and favorable government policies promoting pharmaceutical outsourcing. Additionally, the rising focus on regulatory compliance and quality assurance is influencing CDMOs to adopt Good Manufacturing Practice (GMP) guidelines and implement stringent quality control measures to meet the requirements of the FDA, EMA, and other global regulatory agencies.

A further notable trend is the growing emphasis on accelerated clinical development timelines. With the pharmaceutical industry prioritizing fast-track approvals for breakthrough therapies, CDMOs are enhancing their capabilities to support expedited IND submissions. This includes offering integrated drug development solutions that combine formulation, analytical testing, and clinical trial supply management under a single contract, reducing timelines and improving project efficiency. The increasing adoption of decentralized clinical trials (DCTs) is also influencing CDMOs to adapt their clinical supply chains to meet the demands of remote and hybrid trial models.

What Is Driving the Growth of the IND CDMO Market?

The growth in the Investigational New Drug CDMO market is driven by several factors, including rising pharmaceutical R&D investments, increasing complexity of drug molecules, and the growing need for outsourcing among biopharmaceutical companies. A key driver is the expanding pipeline of novel therapeutics, particularly in oncology, neurology, and rare diseases. With many pharmaceutical firms focusing on precision medicine and targeted therapies, CDMOs are witnessing heightened demand for specialized formulation and analytical services tailored to complex drug candidates.

Another crucial factor propelling market growth is the rising adoption of biologics and cell and gene therapies. The surge in demand for advanced therapeutic modalities has created a need for CDMOs equipped with high-containment manufacturing facilities and expertise in viral vector production, mRNA technology, and regenerative medicine. Furthermore, the increase in orphan drug designations and expedited regulatory pathways, such as the FDA’s Fast Track and Breakthrough Therapy designations, are pushing pharmaceutical firms to seek agile and highly capable CDMO partners to speed up clinical development and regulatory approval processes.

The strategic shift toward virtual biotech models is also fueling demand for IND CDMO services. Many small and mid-sized biotech companies lack in-house manufacturing and regulatory capabilities, making outsourcing an essential strategy for advancing their drug candidates. Additionally, stringent regulatory requirements in early-phase clinical development are compelling pharmaceutical companies to collaborate with experienced CDMOs that offer regulatory consulting, risk mitigation strategies, and GMP-compliant production. Lastly, the growing trend of CDMO partnerships with big pharma to co-develop and manufacture investigational drugs is further driving market expansion, ensuring that innovative therapies reach clinical trials faster while maintaining high-quality standards.

SCOPE OF STUDY:

The report analyzes the Investigational New Drug CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Small Molecule, Large Molecule); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biotech Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• AGC Biologics
• Aurigene Discovery
• Bachem Holding AG
• BioCina
• Biocon
• Cambrex Corporation
• Catalent
• Emergent BioSolutions
• Fujifilm Diosynth
• Hovione
• Jubilant Pharmova
• Laurus Labs
• Lonza Group
• Recipharm AB
• Samsung Biologics
• Siegfried Holding AG
• Syngene International Ltd.
• Thermo Fisher Scientific
• WuXi AppTec
• WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Investigational New Drug CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Outsourcing of Early-Stage Drug Development Strengthens Business Case for IND-Focused CDMOs
  • Surge in Biotech Startup Activity Expands Demand for IND-Enabling Chemistry and Regulatory Support
  • Increasing Complexity of Preclinical and CMC Requirements Spurs CDMO Specialization in IND Preparation
  • FDA Emphasis on Data Integrity and Filing Quality Creates Demand for End-to-End IND Submission Services
  • Acceleration of Rare Disease and Orphan Drug Pipelines Drives IND CDMO Engagements in Niche Therapies
  • Emergence of RNA, Cell, and Gene Therapies Expands Need for Specialized IND-Enabling Manufacturing Platforms
  • Pharma Cost Pressures Fuel Outsourcing of Preclinical Manufacturing and IND Strategy to CDMOs
  • Globalization of Drug Discovery Ecosystems Unlocks Opportunities for Multiregional IND Consulting Services
  • Integration of Regulatory Strategy With CMC Activities Improves IND Timelines and Filing Success
  • Growth in First-in-Human Trials Drives Demand for Small-Scale GMP Production and Stability Testing
  • Increasing Demand for IND Readiness Packages in Accelerated Approval Pathways Spurs Early CDMO Involvement
  • Venture-Backed Biopharma Projects Require Rapid IND Activation, Fueling Agile CDMO Partnerships
  • CDMO Investments in Integrated Bioanalytical Services Expand IND Value Proposition
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Investigational New Drug CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Investigational New Drug CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Large Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 18: USA Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 19: USA 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 20: USA Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 22: USA Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 23: USA 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• CANADA
  • TABLE 24: Canada Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Canada 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Canada 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• JAPAN
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 30: Japan Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Japan 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 34: Japan Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Japan 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• CHINA
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 36: China Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: China 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 38: China Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 40: China Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: China 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• EUROPE
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 42: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 43: Europe 6-Year Perspective for Investigational New Drug CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 46: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Europe 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• FRANCE
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 50: France Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: France 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 52: France Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: France 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 54: France Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: France 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• GERMANY
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 56: Germany Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Germany 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 58: Germany Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Germany 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 60: Germany Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Germany 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• ITALY
  • TABLE 62: Italy Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Italy 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 64: Italy Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Italy 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 66: Italy Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Italy 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• UNITED KINGDOM
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 68: UK Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: UK 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 70: UK Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: UK 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 72: UK Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: UK 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Rest of Europe 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Rest of Europe 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• ASIA-PACIFIC
  • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Asia-Pacific 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Asia-Pacific 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of World 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
  • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of World 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of World 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030

IV. COMPETITION